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Hypospadias, characterized by misplacement of the urinary meatus in the lower side 
of the penis, is a frequent birth defect in male children. Because of the huge variation 
in the anatomic presentation of hypospadias, no single urethroplasty procedure is suit-
able for all situations. Hence, many surgical techniques have emerged to address the 
shortage of tissues required to bridge the gap in the urethra particularly in the severe 
forms of hypospadias. However, the rate of postoperative complications of currently 
available surgical procedures reaches up to one-fourth of the patients having severe 
hypospadias. Moreover, these urethroplasty techniques are technically demanding and 
require considerable surgical experience. These limitations have fueled the development 
of novel tissue engineering techniques that aim to simplify the surgical procedures and to 
reduce the rate of complications. Several types of biomaterials have been considered for 
urethral repair, including synthetic and natural polymers, which in some cases have been 
seeded with cells prior to implantation. These methods have been tested in preclinical 
and clinical studies, with variable degrees of success. This review describes the different 
urethral tissue engineering methodologies, with focus on the approaches used for the 
treatment of hypospadias. At present, despite many significant advances, the search for 
a suitable tissue engineering approach for use in routine clinical applications continues.
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iNTRODUCTiON
Hypospadias is a frequent genitourinary congenital malformation with an incidence of around 1 
per 300 male newborns, although its frequency varies among populations from 0.3 to 7.0 per 1,000 
live births (1, 2). Hypospadias results from the malposition of the urinary meatus on the ventral 
aspect of the penis following incomplete closure of the urethral folds during early gestational weeks. 
This condition has been associated with hereditary and/or environmental factors that have not been 
completely identified yet (3). Three abnormalities that are most frequently associated with hypospa-
dias are an abnormal location of the meatus, a curvature of the penis (chordee), and an incomplete 
ventral prepuce. In general, severe forms of hypospadias are associated with a significant chordee 
and a urethral meatus located proximal to the mid-shaft of the penis. The ventral axis components 
of the penis may also display abnormalities, including atrophy of the cavernous corpora and stiffen-
ing of the corpus spongiosum (4). Advances in microsurgical instrumentation, imaging devices, 
FigURe 1 | The box contains the main limitations of current surgical 
approaches for hypospadias repair. Outside the box, urethral tissue 
engineering approaches that may represent valuable therapeutic options for 
children with severe hypospadias.
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suture materials, and reconstructive techniques have significantly 
improved the outcome of hypospadias surgical repair during the 
last decade. However, the current management techniques for 
proximal hypospadias still present several limitations, which are 
mainly associated with the highly demanding surgical procedures 
and the graft donor site morbidity. Moreover, complication and 
reoperation rates remain unacceptably high. These constraints 
have initiated a drive toward the development of tissue engineer-
ing approaches that may offer a better alternative for pediatric 
urethral reconstruction. In this review, we summarize the limita-
tions of the current surgical management of severe hypospadias 
and examine the recent tissue engineering developments toward 
repair of the urethra, with special focus on the research targeted 
to severe hypospadias in children.
CURReNT MANAgeMeNT OF SeveRe 
HYPOSPADiAS AND iTS LiMiTATiONS
Hundreds of different urethroplasty techniques have been 
reported for hyspospadias repair over the years (5). Treatment of 
distal hypospadias with one-stage urethroplasty approaches, such 
as onlay preputial island flaps or tubularized incised plate (TIP) 
repair, is currently associated with a relatively high success rate. 
However, management of severe hypospadias remains a challenge, 
as no single technique is applicable to all patients. There is still 
an ongoing discussion whether it is most appropriate to perform 
a single-stage or a two-stage approach. Recent reports indicate 
that more patients appear to develop complications following 
single-stage procedures (6) and that staged procedures may 
result in overall better functional outcomes (7). Yet, retrospective 
studies of patients undergoing two-stage repair have evidenced 
complication rates ranging from 50 to 68% (8, 9). The frequency 
of postoperative complications appears to increase with the ana-
tomic severity of hypospadias no matter what surgical technique 
is employed (6). The most frequent complications include fistulas 
and urethral strictures, but can also include dehiscence of the 
repair or recurrence of chordee.
The outcome of the urethroplasty not only depends on the 
quality of the anatomical structures and the surgical approach but 
also on the availability of an appropriate source for the graft, since 
patients with severe hypospadias frequently require extra tissue to 
restore the missing urethra. Autologous sources of grafts utilized 
for urethral replacement include skin from genital areas or extra-
genital regions (10–12). These grafts have been superseded by 
buccal mucosa free skin grafts which is currently the most widely 
used source (13). Harvesting of oral mucosal grafts represents an 
easy procedure, causing minimal discomfort for the patient and 
an acceptable degree of morbidity (14). However, the amounts of 
tissue available for harvesting are limited and complications may 
appear, including donor site bleeding, infection, pain, parotid 
duct injury, graft contracture, and numbness (15).
Further complexities may arise following the pubertal period, 
in that a failed neo-urethra may result in a scarcity of hair-free 
surrounding skin for urethral replacement. Moreover, a surgi-
cally constructed neo-urethra may fail to develop along with the 
penis as the affected person matures to post-pubertal age, causing 
stricture and secondary chordee. Balanitis xerotica obliterans, 
resulting from the use of adjacent affected urethral or penile 
tissues for repair, may also cause recurrent urethral strictures in 
patients who had undergone previous surgery for hypospadias. 
Eventually, any form of substitution urethroplasty seems to 
worsen over time, as complication rates appear to increase with 
the duration of the follow-up (16).
THe RiSe OF UReTHRAL TiSSUe 
eNgiNeeRiNg
Overall, the disappointingly low success rates, the complications 
related to graft harvesting, and the tendency of grafts to dete-
riorate over time, are prompting us “to think outside the box” 
(Figure 1). Tissue engineering may hold the key to finding novel 
techniques and tissue sources to replace the missing urethra. 
Tissue-engineered grafts could be tailored with characteristics 
like those of urethral mucosa, but conveniently available “off the 
shelf.” Ideally, tissue-engineered constructs for urethral replace-
ment should be biocompatible, able to be well vascularized and 
biodegradable (17, 18). The biodegradation process should follow 
with the regeneration timeframe of the local surrounding tissues 
to allow the generation of a fully differentiated functional urothe-
lium (19). Moreover, optimal constructs should also be compliant 
enough to accommodate jets of propelled urine during voiding. 
Neo-urethral compliance can be adjusted by manipulating the 
mechanical properties of constructs to optimize stretch function-
ality (20). Furthermore, the construct should be impermeable to 
urine, as urine is cytotoxic to surrounding tissues (21).
To overcome the difficulties associated with current urethral 
repair techniques, during the last couple of decades, extensive 
TAbLe 1 | Examples of biomaterials and cells that have been investigated for 
urethral tissue engineering.
examples Reference
Synthetic biomaterial scaffolds
Polyethylene terephthalate (23)
Poly (l-lactic acid)-co-poly-(ε-caprolactone) (PLLCL) (26)
Polylactic acid/PLLCL composite (27)
Natural biomaterial scaffolds
Collagen type I and III (28)
Silk fibroin (31, 61, 62)
Small intestine submucosa (SIS) (35–37)
Decellularized human amniotic membrane (39)
Decellularized urinary bladder (34)
Decellularized porcine dermis (38)
Cells
Urine-derived stem cells (48)
Urothelial cells derived from bladder washes (45, 46)
Adipose-derived stromal cells (57, 58)
Oral keratinocytes (63)
3
Abbas et al. Tissue Engineering for Hypospadias Management
Frontiers in Pediatrics | www.frontiersin.org January 2018 | Volume 5 | Article 283
research has been performed to investigate biomaterials and cells 
that could be used alone or in combination for urethral replace-
ment. Table  1 provides some examples of the diverse types of 
biomaterials and cells that have been assessed for urethral tissue 
engineering. These sources will be described and discussed in the 
following sections.
POLYMeRiC AND eXTRACeLLULAR 
MATRiX (eCM)-DeRiveD SCAFFOLDS
The scaffold acts as a supporting skeleton for tissue regeneration, 
maintaining the structural balance of the regenerating tissue and 
allowing its three-dimensional (3D) regeneration. The scaffolds 
can be categorized according to their biodegradability (non-
biodegradable or biodegradable) or according to their source 
(synthetic, naturally derived, or a combination of both) (22).
Some of the synthetic non-degradable polymers that have 
been explored for urinary tract reconstruction include polytetra-
fluoroethylene and poly(ethylene terephthalate). These materials 
do not readily promote cellular attachment and, therefore, 
require a surface treatment to allow for urothelial cell adhesion 
(23). In general, non-degradable materials used in urinary tract 
reconstruction have been mainly used as temporary supports in 
specific clinical scenarios, as they have in general exhibited poor 
results, with the occurrence of complications including calcifica-
tion, fistulae, chronic hematuria, encrustation, migration, and 
significant shortening (24, 25).
Synthetic biodegradable scaffolds, on the other hand, include 
those made of polymers, including poly-l-lactide (PLL), polycap-
rolactone (PCL), and poly(lactic-co-glycolic acid) (PLGA). The 
mechanical properties of these polymers, such as porosity and 
degradation rate, can be easily tailored to satisfy the requirements 
of a urethral construct. Polymeric composite membranes fabri-
cated using PLL–PCL have demonstrated to possess mechanical 
properties suitable for urothelial tissue engineering, supporting 
growth and phenotype maintenance of human urothelial cells 
(26, 27). Synthetic biomaterials, however, usually require surface 
treatments to promote cell attachment, as they lack specific 
molecular elements for interaction with cells and proteins (22).
Natural polymers, on the other hand, exhibit specific cell 
adhesion ligands that favor the attachment and growth of cells 
onto their surface. Different naturally derived biomaterials have 
been explored for urethral replacement, including collagen (28), 
hyaluronic acid derivatives, alginate, and chitosan (29). Another 
promising biomaterial is silk fibroin (SF), a natural polymer 
obtained from Bombyx mori cocoons. This material has shown 
excellent biocompatibility, with reduced immunogenicity and 
fewer inflammatory reactions as compared to other biological 
materials. The mechanical characteristics of SF, including its 
elasticity and shape memory, were found to be well suited for 
urologic tissue engineering applications (30). Different cell types 
relevant for urethral reconstruction have been successfully grown 
onto porous SF scaffolds, including keratinocytes and fibroblasts 
(31). SF can also be blend with a synthetic polymer, such as PCL, 
to facilitate the fabrication of electrospun nanofiber allowing suc-
cessful growth of oral mucosal epithelial (EP) cells (32).
Extracellular matrix obtained after chemical decellularization of 
xenogeneic or allogeneic tissues has also been extensively investi-
gated as a scaffold for urethral reconstruction. ECM scaffolds exhibit 
very rapid biodegradability in vivo, releasing degradation compo-
nents that orchestrate healing and regeneration through a process 
known as constructive tissue remodeling (33). Decellularized 
tissues retain most of the structural collagens and proteoglycans, 
which contribute not only to preserve the structural integrity 
but also to retain bioactive growth factors promoting ingrowth 
of endothelial and smooth muscle cells (SMCs) (34). Matrices 
prepared from small intestine submucosa (SIS) are those that have 
been most frequently investigated for urethral repair, thanks to 
their high content of collagens, fibronectin, elastin, and glycosami-
noglycans (35–37). Other acellular matrices include decellularized 
porcine dermis (38), human amniotic membrane (39), and urinary 
bladder (40). A promising new source for generation of autologous 
tissue-engineered constructs is decellularized ECM obtained from 
cultures of progenitor cells (41, 42). These in  vitro cell-derived 
matrices might be prepared using urethral-specific cells to provide 
a mixture of specific ECM components and biological factors that 
may provide the environmental signals controlling the fate of the 
diverse types of cells comprising the urethral tissue.
CeLL-SeeDeD SCAFFOLDS
No consensus has yet been reached on the potential beneficial 
effects of cell seeding of tissue-engineered scaffolds for use in the 
urogenital system, although it appears that cells are required for 
urethral repair of defects that are >0.5 cm in length (43). Although 
cells harvested from the urinary tract may be the optimal choice 
for urethral tissue engineering, other sources may be effective as 
well. A recent study was performed to determine whether EP cells 
from urinary and non-urinary sources may behave different in 
terms of their clonogenic capacity and ability to proliferate. Since 
only few differences were observed between oral mucosal and 
urethral cells, the authors suggested that these two sources may 
be similarly efficient to generate stratified epithelium for urethral 
reconstruction (44).
FigURe 2 | Fabrication of urethral scaffold tubes: (A) A matrix sheet of fibroblasts is rolled to form a tube, and urothelial cells are seeded in the lumen. (b) Illustration 
of a bioreactor for tubular cell-seeded grafts to stimulate differentiation and formation of a watertight mucosal layer [reprinted with permission from Ref. (49)]. © 2013 
by Orabi et al.
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Several studies have examined the effects of seeding scaf-
folds with urothelial cells, which may be obtained invasively or 
non-invasively. Disadvantages of invasive techniques (e.g., open 
bladder biopsy) include the harvesting of an inadequate number 
of cells and their requirement for general anesthesia. Moreover, 
the associated morbidity of the donor site can lead to significant 
risks, including bleeding and infection. Alternatively, various 
non-invasive methods have been used to harvest the needed cells 
as well. For example, urothelial cells have been obtained from 
bladder washings, a method that has shown to be safe and highly 
reproducible in adults and children (45, 46). Urine-derived stem 
cells have also shown the ability to expand and to differentiate 
into both urothelial and smooth muscle phenotypes (47, 48). Cell 
proliferation is markedly influenced by the mechanical proper-
ties of the polymer scaffolds, and coculture of several cell types 
was shown to be superior to culture of individual cell types (38), 
perhaps because the former represents a more physiological con-
dition, involving paracrine signaling among different cell types.
FAbRiCATiON AND ADDiTiON OF 
biOACTive FACTORS
Although several approaches have been utilized to fabricate 
these scaffolds, an attractive method of fabricating scaffolds for 
urethral replacement consists of producing cell-seeded tubular 
grafts that self-assemble (Figure 2) (49). Optimal results require 
adjusting the mechanical properties of these constructs, includ-
ing surface topography that is important for ideal growth and 
differentiation of the cells. For example, attachment of cellular 
proteins important for urothelial cell adhesion can be enhanced 
by increasing the external roughness of these scaffolds (50, 51). 
Scaffold porosity is another parameter that needs to be controlled 
during fabrication to offer a route for the diffusion of nutrients to 
the cells, as well as for the elimination of metabolic products (52, 
53). Exogenous trophic factors, including natural ECM proteins 
and growth factors, have been used to bio-functionalize scaffolds 
creating a microenvironment that simulates the integration of the 
tissue-engineered constructs (54–56).
ReCeNT TRANSLATiONAL AND CLiNiCAL 
STUDieS TOwARD TiSSUe-eNgiNeeReD 
UReTHRAL RePLACeMeNT
Several engineered urethral substitutes have been examined 
in animal models over the past three decades. Although some 
studies have demonstrated positive results, the experiments were 
performed in small series with short follow-up. Notwithstanding, 
the results of these animal studies have yielded several important 
conclusions. For example, failure of a urothelial layer to develop 
on the internal surface of the implanted constructs resulted in 
leakage of urine, with associated inflammation and fibrosis, lead-
ing to re-stricturing. Moreover, seeded constructs seem necessary 
to treat longer strictures, because the survival of these constructs 
does not depend on the ingrowth of EP cells from the surround-
ing healthy tissues but mainly on the pre-seeded cells (49). Efforts 
to identify better cell sources to seed the constructs have led to the 
use of adipose stem cells to reconstruct urinary tract epithelium 
(24, 57, 58) and SMCs (59) in urethral tissue engineering. A recent 
systematic review showed that, regardless of the type of scaffold 
material, cell seeding significantly reduced the risk of morbidities. 
Moreover, the addition of cells reduced failure rates when inlay or 
full urethroplasties were performed (60).
On the other hand, extent of vascularization represents a key 
factor for the success of the implanted constructs. In this direc-
tion, vascularization has been analyzed immunohistochemically 
in a rabbit model following ventral onlay grafts of SF (Figure 3). 
The samples of tissue-engineered urethra revealed SMC differen-
tiation, EP maturation, and de novo vascularization and inner-
vation processes (61). Several other preclinical studies strongly 
support the use of SF as a material for urethral tissue engineering, 
showing improved vascularization and reduced immunogenicity 
in comparison to conventional SIS scaffolds (61, 62).
When considering the type of the reconstruction and the 
related shape of the construct, animal studies showed that 
synthetic materials did not perform as well for inlay repair as 
compared to full repair (60). It is also desirable to produce an arti-
ficial graft with characteristics similar to those of buccal mucosa 
FigURe 3 | Urethral tissue regeneration following implantation of acellular silk fibroin scaffolds in rabbits. (A) Immunohistochemical assays showing the expression 
of smooth muscle (SM) contractile markers; epithelial (EP)-associated cytokeratins (CK); and endothelial markers. V indicates blood vessels and arrows denote cells 
of neuronal lineages. Scale bars denote 200 µm in all panels. Panels (b–D) display histomorphometric data from alpha-smooth muscle actin positive (a-SMA+) 
regions (b), CK positive cells (C), and CD31 positive vessels (D) obtained from control and scaffold implanted animals. [reprinted with permission from Ref. (61)].  
© 2014 by Chung et al.
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and a tissue-engineered buccal mucosa for urethral replacement 
showed optimal short-term results in a rabbit model (63). Long-
term results, on the other hand, showed that the collagen fibers 
in the construct were significantly more disordered than those in 
normal urethral submucosa (64).
Intriguingly, a recent meta-analysis comparing outcomes of 
several urethral tissue engineering preclinical and clinical studies 
has revealed that the favorable results seen in animal models are 
not always translated into the patients (60). A feasible explana-
tion for these differences could be the fact that preclinical studies 
use animal models with a healthy urethra, limiting the level of 
evidence provided by the animal model.
Concerning clinical trials, several studies have been carried 
out to assess the performance of tissue-engineered grafts in pedi-
atric patients (summarized in Table 2). In general, results using 
scaffolds or tissue-engineered constructs have been suboptimal 
in patients who had preceding failed urethroplasties and those 
with unhealthy vascular beds (65).
In 1999, Atala et al. showed that the use of bladder submucosa 
and a collagen-based inert matrix for urethroplasty in four patients 
with hypospadias yielded positive results (13). Despite the small 
number of patients, the short duration of follow-up (22 months) 
and the development of a fistula in one patient, these findings 
suggest that tissue-engineered materials should be tested in larger 
numbers of patients. 10 years later, use of a porous gelatin scaf-
fold and preputial mucosa or a urethral plate graft combined with 
local flap to repair severe hypospadias in eight patients revealed 
that all were successful after 1-year follow-up (66).
A porous gelatin scaffold was also shown to be successful 
in eight patients with hypospadias, of mean age 13 years in a 
consecutive experiment (40). Another clinical trial, in which 
patients were followed up for 6  years, found that tubularized 
constructs composed of PGA:PLGA meshes seeded with 
bladder cells were successful in managing urethral trauma 
in pediatric patients (67). However, degradation products of 
polyester-based scaffolds can induce chronic inflammation 
TAbLe 2 | Outcomes of clinical studies of tissue-engineered urethral replacement in pediatric patients [adapted from Ref. (15, 60)].
Material Approach Number of 
patients
Age Follow-up Outcome Reference
Collagen-based matrix O 4 4–20 years 22 months Three patients had successful cosmetic and functional outcomes (13)
Gelatin sponge – 8 8–36 months 12 months Implants were successful in all patients (66)
Acellular skin, human C 8 4–23 years 4–6 months Implants were similarly successful in all patients (40)
PGA and PLGA C 5 10–14 years 36–76 months Implants were successful in all patients (67)
Acellular skin, human O 6 14–44 months 6–8 years All patients had good functional and cosmetic results (70)
SIS, 4-layer, porcine O 12 1.5–15 years 6–36 months Implants were successful. Three patients developed fistulas  
and failure of the graft
(71)
O, onlay; C, circumferential; PGA, polyglycolic acid; PLGA, poly(lactide-co-glycolic acid); SIS, small intestine submucosa.
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in vivo (68) and may, therefore, adversely affect the long-term 
fate of implanted constructs (69).
In 2013, Fossum et al. tested the long-term (about 8 years) 
effects of cultured autologous urothelial cell implants in 
hypospadias patients (70). That study found that use of these 
implants in patients with severe hypospadias resulted in high 
complication rates, but with results equal to or better than 
expected for their phenotypes. However, the limitations of this 
study included the small number of patients and the absence of 
a control group.
A recent clinical study found that SIS grafts were successful 
in circumcised patients with hypospadias or undergoing repeat 
hypospadias repair (71) (Figure  4). Three of the 12 patients 
developed fistula, which may have been caused by the occurrence 
of infection, but these fistulas were easy to repair. Limitations 
included the heterogeneity of the hypospadias (distal, mid-shaft, 
and proximal), the heterogeneity of patient age (from infants to 
teenagers), and the inclusion of untreated patients and those who 
had failed previous repair, all of which might generate confusion 
in the interpretation of results.
CONCLUSiON AND FUTURe DiReCTiONS
Current urethroplasty techniques for the management of severe 
hypospadias are associated with significant morbidities and 
limitations that strongly mandates the need to “think outside 
the box.” Advances in urethral tissue engineering biomaterials 
and fabrication methods have built a solid base on which future 
urethral replacement approaches can stand on. The currently 
available experimental evidence suggests that long and complex 
urethral defects would require tubular cell loaded constructs in 
contrast to onlay grafts, which have shown benefit in shorter 
defects. Although the search for an “ideal” combination of bio-
materials and cells for urethral replacement continues, it appears 
that optimal results could be obtained with composite materials 
seeded what different cell types (stromal and EP). Future research 
in this field should take into consideration more realistic animal 
models to bridge the translational gap between animal models and 
clinical studies and the importance of longer follow-up periods. 
We believe that biodegradability is a crucial factor for successful 
urethral tissue-engineered regeneration in children, which may 
accompany the natural growth of penile size at puberty.
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FigURe 4 | (A) Gross appearance of a small intestine submucosa (SIS) graft; (b) penile skin degloving through a subcoronal incision, preserving the urethral plate; 
(C) suturing of the SIS graft in an onlay fashion; (D) suturing of the completed onlay SIS graft; (e) splitting of the dartos flap into two halves to form the second layer 
of coverage for the graft; and (F) final postoperative appearance [reprinted with permission from Ref. (71)]. © 2013 by Elsevier B.V.
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